StephenPatrickAnthonyDO

Oncology • Spokane, WA

Breast Cancer, Gynecologic Cancer, Hematologic Oncology

President, Evergreen Hematology and Oncology

Join to view full profile

Dr. Anthony is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Anthony's full profile

Already have an account?

Office
309 E Farwell Rd
Suite 100
Spokane, WA 99218
Phone+1 509-464-2873

Fax+1 509-466-0914

Education & Training

Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 1994 - 1997
Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 1989 - 1992
Philadelphia College of Osteopathic MedicineClass of 1988

Certifications & Licensure

TN State License 2021 - 2026
TX State License 2017 - 2026
AZ State License 2006 - 2025
WA State License 1998 - 2025
VT State License 1996 - 1998
PA State License 1989 - 1994
American Board of Internal Medicine Medical Oncology

Clinical Trials

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer Start of enrollment: 2003 May 01
Unknown status
Phase 1
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Mar 01
Completed
Phase 1
Safety Study of PLX108-01 in Patients With Solid Tumors Start of enrollment: 2009 Oct 01
Completed
Phase 1
Pilot Study Using Molecular Profiling to Find Potential Targets & Select Treatments for Pts With Met br ca Start of enrollment: 2010 Mar 01
Completed
Early Phase 1
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer Start of enrollment: 2011 Nov 01
Completed
Phase 1, Phase 2
FoundationOne™ Test Registry Study Start of enrollment: 2013 Mar 01
Completed
A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer Start of enrollment: 2013 Aug 01
Completed
Not Applicable
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL Start of enrollment: 2019 Jun 10
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

5 citations
CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden.
Charles Peterfy, Yan Chen, Peter Countryman, Bartosz Chmielowski, Stephen P Anthony
Future Oncology. 2022-04-01
3 citations
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia
Joshua F. Zeidner, Tara L. Lin, Carlos E. Vigil, Gil Fine, M. Yair Levy
Blood Cancer Journal. 2021-10-30
12 citations
Results from Phase 1 Extension Study Assessing Pexidartinib Treatment in 6 cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
William D. Tap, Arun S. Singh, Stephen P. Anthony, Mike Sterba, Chao Zhang
Clinical Cancer Research. 2021-10-29

Lectures

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Professional Memberships

American Society of Clinical Oncology - ASCO
Member